Esperion Rises as Cholesterol Drug Can Forgo Heart Trial

Updated on

Esperion Therapeutics Inc. said U.S. regulators won’t require a trial to determine the effects of its experimental cholesterol drug on heart health, smoothing the path toward approval.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.